Chem. J. Chinese Universities ›› 2021, Vol. 42 ›› Issue (11): 3390.doi: 10.7503/cjcu20210257

• Review • Previous Articles     Next Articles

Lateral Flow Assay Based on Molecular Recognition for Diagnosis of Corona Virus Disease 2019 Infection

LIU Yuan1,2, DENG Jinqi2, ZHAO Shuai2, TIAN Fei2(), LI Yi1(), SUN Jiashu2,3, LIU Chao2,3()   

  1. 1.Tianjin Key Laboratory of Molecular Optoelectronic Sciences,Department of Chemistry,School of Science,Tianjin University & Collaborative Innovation Center of Chemical Science and Engineering,Tianjin 300072,China
    2.Beijing Engineering Research Center for BioNanotechnology,CAS Key Laboratory of Standardization and Measurement for Nanotechnology,CAS Center for Excellence in Nanoscience,National Center for Nanoscience and Technology,Beijing 100190,China
    3.School of Future Technology,University of Chinese Academy of Sciences,Beijing 100049,China
  • Received:2021-04-19 Online:2021-11-10 Published:2021-11-10
  • Contact: TIAN Fei,LI Yi,LIU Chao E-mail:tianf@nanoctr.cn;liyi@tju.edu.cn;liuc@nanoctr.cn

Abstract:

The novel coronavirus disease 2019(COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is still spreading worldwide. Rapid screening and isolation of infected individuals, including asymptomatic individuals, is one of the key steps to control the epidemic. Lateral flow assay is a mature technique for point-of-care detection. Owing to its advantages of simple operation, fast response and robustness, lateral flow assay has been a powerful tool for rapid detection of biomarkers. This paper summarized the recent research progresses of lateral flow assays for the diagnosis of COVID-19 infection, with antibody, protein, or nucleic acid as detection targets, and the advantages and limitations of different detection methodologies were shortly discussed. Finally, we briefly introduced the currently commercialized lateral flow test strips for COVID-19 diagnostics.

Key words: Molecular recognition, Lateral flow assay, Corona virus disease 2019, Severe acute respiratory syndrome coronavirus 2, Point-of-care testing

CLC Number: 

TrendMD: